Vanta Bioscience (Small Cap) Share Target 2024, 2025 To 2039
|
Vanta Bioscience Limited |
|||
|
Price: ₹42.47 | ||
| 52 Week Low: ₹37.01 52 Week High: ₹101.64 |
|||
| Market Capital: 44.18 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Vanta Bioscience Share Price Target For 2024
- 1.1.1: Vanta Bioscience Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Vanta Bioscience Share Price Target For 2025
- 1.2.1: Vanta Bioscience Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Vanta Bioscience Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Vanta Bioscience Financial Performance
- 3.0.1: Is Vanta Bioscience A Good Buy For Long Term?
To predict the Vanta Bioscience's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Vanta Bioscience Share Price Target For 2024
The line chart displays the monthly closing prices of Vanta Bioscience with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Vanta Bioscience shares in 2024, see the table below.
Vanta Bioscience Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 45.62 (+7.41%) | Price Action: 11 Nov 2024 Low |
| 2024 Target 2 | 45.0 (+5.95%) | Price Action: 08 Nov 2023 High |
| 2024 Target 1 | 44.37 (+4.47%) | Price Action: 11 Sep 2024 Low |
| Current Price | 42.47 | Vanta Bioscience's share price as of 24 Dec 2024 |
| Stop Loss 1 | 41.52 (-2.24%) | Price Action: 14 Nov 2024 High |
| Stop Loss 2 | 41.07 (-3.3%) | Price Action: 19 Nov 2024 High |
| Stop Loss 3 | 40.6 (-4.41%) | Price Action: 16 Oct 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Vanta Bioscience is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹44.49 serves as the nearest technical reference point.
Historical Returns: 3-month: -16.71% | 6-month: -18.32% | 1-year: -20.69%
Vanta Bioscience Share Price Target For 2025
The line chart displays the monthly closing prices of Vanta Bioscience with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Vanta Bioscience shares in 2025, see the table below.
Vanta Bioscience Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 83.68 (+97.03%) | Price Action: 23 Feb 2024 High |
| 2025 Target 2 | 82.11 (+93.33%) | Price Action: Chart |
| 2025 Target 1 | 81.3 (+91.42%) | Price Action: 14 Mar 2024 High |
| Current Price | 42.47 | Vanta Bioscience's share price as of 24 Dec 2024 |
| Stop Loss 1 | 32.26 (-24.05%) | Price Action: Chart |
| Stop Loss 2 | 31.94 (-24.8%) | Price Action: Chart |
| Stop Loss 3 | 31.37 (-26.14%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Vanta Bioscience is currently trading near its 52-week low of ₹37.01, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -20.69% | 3-year: -66.48% | 5-year: -61.67%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Vanta Bioscience Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹42.47 | ||
| 2024 | ₹43.75 | +3.01% | ₹46.17 |
| 2025 | ₹31.24 | -28.59% | ₹43.79 |
| 2026 | ₹36.56 | +17.02% | ₹39.67 |
| 2027 | ₹38.87 | +6.31% | ₹42.39 |
| 2028 | ₹38.40 | -1.2% | ₹42.86 |
| 2029 | ₹44.80 | +16.66% | ₹48.20 |
| 2030 | ₹44.73 | -0.15% | ₹48.88 |
| 2031 | ₹39.75 | -11.13% | ₹45.24 |
| 2032 | ₹37.93 | -4.57% | ₹41.59 |
| 2033 | ₹46.54 | +22.69% | ₹73.08 |
| 2034 | ₹46.27 | -0.58% | ₹73.66 |
| 2035 | ₹44.49 | -3.84% | ₹74.76 |
| 2036 | ₹45.39 | +2.02% | ₹76.49 |
| 2037 | ₹42.08 | -7.29% | ₹76.56 |
| 2038 | ₹39.69 | -5.67% | ₹79.16 |
| 2039 | ₹79.69 | +100.78% | ₹80.89 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Vanta Bioscience Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 44.18 Crore | Market valuation of Vanta Bioscience's shares. |
| Revenue (TTM) | 6.27 Crore | Total revenue generated by Vanta Bioscience over the past twelve months. |
| Net Income (TTM) | -6.48 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -74.22% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +84.24% | Net income as a percentage of revenue, after all expenses. |
| Debt-to-Equity (D/E) Ratio |
2.95 | Company's total debt divided by total shareholder equity. |
| Total Debt | 57.11 Crore | Sum of Vanta Bioscience's current & long-term financial obligations. |
Is Vanta Bioscience A Good Buy For Long Term?
Vanta Bioscience, a small-cap stock with a volatile history, shows mixed financial performance. Its recent revenue growth is promising, but its profitability remains a concern with negative net income. The high debt level of 57.11 Crore raises financial risk. While past returns have been positive in the short term, long-term returns have been negative. Given these factors, Vanta Bioscience may be considered an average buy for investors seeking moderate risk with the potential for growth, but caution is advised due to its financial vulnerabilities.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
